SCVI3438
The cell line is not validated yet.
SCVIi113-A
General
iPSC Line |
|
| hPSCreg name | SCVIi113-A |
| Cite as: | SCVIi113-A (RRID:CVCL_D6LV) |
| Alternative name(s) |
SCVI3438
|
| iPSC line type | Human induced pluripotent stem cell (hiPSC) |
| Similar iPSC lines | No similar lines found. |
| Last update | 26th May 2026 |
| User feedback | |
Provider |
|
| Generator | Stanford Cardiovascular Institute (SCVI) |
| Owner | Stanford Cardiovascular Institute (SCVI) |
| Distributors | |
| Derivation country | United States |
External iPSC Databases |
|
| Cellosaurus | CVCL_D6LV |
| Wikidata | Q127384250 |
| BioSamples | SAMEA122697056 |
General iPSC Information |
|
| * Is the cell line readily obtainable for third parties? |
Yes Research use: allowed
Clinical use: allowed
Commercial use: allowed
Additional restrictions:
Cell line can be used with an approved MTA |
Donor Information
General Donor Information |
|
| Sex | female |
| Ethnicity | White/Not Hispanic or Latino |
Phenotype and Disease related information (Donor) |
|
| Diseases | A disease was diagnosed.
|
| Family history | None |
Karyotyping (Donor) |
|
| Has the donor karyotype been analysed? |
Yes
46, XX
Karyotyping method:
Molecular karyotyping by SNP array
http:// |
Other Genotyping (Donor) |
|
| Is there genome-wide genotyping or functional data available? |
No
|
External Databases (Donor) |
|
| BioSamples | SAMEA122697058 |
Ethics
| Has informed consent been obtained from the donor of the embryo/tissue from which the pluripotent stem cells have been derived? | Yes |
| Was the consent voluntarily given? | Yes |
| Has the donor been informed that participation will not directly influence their personal treatment? | Yes |
| Can you provide us with a copy of the Donor Information Sheet provided to the donor? | No |
| Do you (Depositor/Provider) hold the original Donor Consent Form? | No |
| If you do not hold the Donor Consent Form, do you know who does? | Yes |
| Please indicate whether the data associated with the donated material has been pseudonymised or anonymised. | anonymised |
| Does consent explicitly allow the derivation of pluripotent stem cells? | No |
| * Does consent expressly prevent the derivation of pluripotent stem cells? | No |
| * Does consent pertain to a specific research project? | No |
| Does consent prevent CELLS DERIVED FROM THE DONATED BIOSAMPLE from being made available to researchers anywhere in the world? | No |
| How may genetic information associated with the cell line be accessed? | Controlled Access |
| Will the donor expect to receive financial benefit, beyond reasonable expenses, in return for donating the biosample? | No |
| Has a favourable opinion been obtained from a research ethics committee, or other ethics review panel, in relation to the Research Protocol including the consent provisions? | Yes |
| Name of accrediting authority involved? | Stanford IRB committee |
| Approval number | 29904 |
| For generation of the cell line, who was the supplier of any recombined DNA vectors or commercial kits used? |
iPSC Derivation
General |
|
| Source cell type |
Mononuclear cells collected from peripheral blood.
Synonyms
|
Reprogramming method |
|
| Vector type | Non-integrating |
| Vector | Sendai virus |
| Genes | |
| Is reprogramming vector detectable? |
No |
| Methods used |
RT-PCR
|
| Files and images showing reprogramming vector expressed or silenced | |
Vector free reprogramming |
|
Other |
|
| Derived under xeno-free conditions |
Unknown |
| Derived under GMP? |
Unknown |
| Available as clinical grade? |
Unknown |
iPSC Culture Conditions
| Surface coating | Matrigel/Geltrex |
| Feeder cells |
No |
| Passage method |
Enzyme-free cell dissociation
EDTA
|
| O2 Concentration | 20 % |
| CO2 Concentration | 5 % |
| Medium |
Other medium:
Base medium: StemMACS™ iPS-Brew XF, human
Main protein source: Serum concentration: % |
| Has Rock inhibitor (Y27632) been used at passage previously with this iPSC line? | Yes |
| Has Rock inhibitor (Y27632) been used at cryo previously with this iPSC line? | No |
| Has Rock inhibitor (Y27632) been used at thaw previously with this iPSC line? | Yes |
iPSC Characterisation
Analysis of undifferentiated iPSCs
| Marker | Expressed | Immunostaining | RT-PCR | Flow Cytometry | Enzymatic Assay | Expression Profiles |
| NANOG |
Yes |
|||||
| SOX2 |
Yes |
|||||
| POU5F1 (OCT-4) |
Yes |
Morphology pictures
Differentiation Potency
Genotyping
Karyotyping (iPSC Line) |
|
| Has the iPSC line karyotype been analysed? |
Yes
46, XX
Karyotyping method:
Molecular karyotyping by SNP array
http:// |
Other Genotyping (iPSC Line) |
|
Login to share your feedback, experiences or results with the research community.